Lenalidomide in myeloma--a high-maintenance friend.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed.

1. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma.Blood · 2014
   Trial
2. Treatment trade-offs in myeloma: A survey of consecutive patients about contemporary maintenance strategies.Cancer · 2013
   Trial
3. Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions.Current research in pharmacology and drug discovery · 2022
   Review
4. Multicomponent reactions (MCRs): a useful access to the synthesis of benzo-fused γ-lactams.Beilstein journal of organic chemistry · 2019
   Review
5. Immunomodulatory drugs downregulate IKZF1 leading to expansion of hematopoietic progenitors with concomitant block of megakaryocytic maturation.Haematologica · 2018
   Article
6. Multiple myeloma cells' capacity to decompose HBlood · 2017
   Article
7. Arsenic trioxide and triptolide synergistically induce apoptosis in the SKM‑1 human myelodysplastic syndrome cell line.Molecular medicine reports · 2016
   Article
8. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma.Bone marrow transplantation · 2014
   Article
9. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma.Therapeutic advances in hematology · 2013
   Review
10. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.Leukemia · 2013
    Article
11. Minimal residual disease in multiple myeloma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Article
12. Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.Nature reviews. Clinical oncology · 2012
    Article

Corrections and comments

• Comment on
  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.2012
• Comment on
  Lenalidomide after stem-cell transplantation for multiple myeloma.2012
• Comment on
  Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as